Veradermics Incorporated (NYSE:MANE) on Wednesday released topline results from an open-label Phase 2 trial evaluating its experimental VDPHL01 in women with mild-to-moderate pattern hair loss.
The company said the treatment produced consistent hair growth, demonstrated an early onset of activity, and was generally well tolerated, positioning it as a potential first FDA-approved oral therapy for female pattern hair loss.
Read Also: Q32 Bio Stock Soars After Patchy Hair Loss Study – Here's Why Veradermics Reports Positive Phase 2 Results For VDPHL01 The Phase 2 Study '207' evaluated VDPHL01 at a 4.5-milligram once-daily dose and a 4.5-milligram twice-daily dose over six months.
According to the company, participants in both treatment groups experienced clinically meaningful improvements in non-vellus target area hair count.
Women receiving the once-daily regimen recorded an average increase of 22.7 hairs per square centimeter, while those receiving the twice-daily regimen saw an average increase of 23.3 hairs per square centimeter.
